465 related articles for article (PubMed ID: 21343919)
1. Opioid-induced constipation: challenges and therapeutic opportunities.
Camilleri M
Am J Gastroenterol; 2011 May; 106(5):835-42; quiz 843. PubMed ID: 21343919
[TBL] [Abstract][Full Text] [Related]
2. Methylnaltrexone for the treatment of opioid-induced constipation.
Bader S; Dürk T; Becker G
Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):13-26. PubMed ID: 23265145
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of constipation in chronic pain patients].
Shimoyama N; Shimoyama M
Masui; 2013 Jul; 62(7):822-8. PubMed ID: 23905405
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
[TBL] [Abstract][Full Text] [Related]
6. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
van Malderen K; Halawi H; Camilleri M
Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
[TBL] [Abstract][Full Text] [Related]
7. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?
Holzer P
Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544
[TBL] [Abstract][Full Text] [Related]
8. Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit.
Arpino PA; Thompson BT
J Clin Pharm Ther; 2009 Apr; 34(2):171-5. PubMed ID: 19250137
[TBL] [Abstract][Full Text] [Related]
9. Opioid-induced constipation.
Gyawali B; Hayashi N; Tsukuura H; Honda K; Shimokata T; Ando Y
Scand J Gastroenterol; 2015; 50(11):1331-8. PubMed ID: 26061717
[TBL] [Abstract][Full Text] [Related]
10. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach.
Reimer K; Hopp M; Zenz M; Maier C; Holzer P; Mikus G; Bosse B; Smith K; Buschmann-Kramm C; Leyendecker P
Pharmacology; 2009; 83(1):10-7. PubMed ID: 18957874
[TBL] [Abstract][Full Text] [Related]
11. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.
Paulson DM; Kennedy DT; Donovick RA; Carpenter RL; Cherubini M; Techner L; Du W; Ma Y; Schmidt WK; Wallin B; Jackson D
J Pain; 2005 Mar; 6(3):184-92. PubMed ID: 15772912
[TBL] [Abstract][Full Text] [Related]
12. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
Mueller-Lissner S
Adv Ther; 2010 Sep; 27(9):581-90. PubMed ID: 20714946
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms that underlie μ-opioid receptor agonist-induced constipation: differential involvement of μ-opioid receptor sites and responsible regions.
Mori T; Shibasaki Y; Matsumoto K; Shibasaki M; Hasegawa M; Wang E; Masukawa D; Yoshizawa K; Horie S; Suzuki T
J Pharmacol Exp Ther; 2013 Oct; 347(1):91-9. PubMed ID: 23902939
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
[TBL] [Abstract][Full Text] [Related]
15. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
Candiotti KA; Gitlin MC
Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
17. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
18. [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction].
Meerpohl JJ; Timmer A
Z Gastroenterol; 2008 Sep; 46(9):917-21. PubMed ID: 18810678
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
[TBL] [Abstract][Full Text] [Related]
20. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
Clemens KE; Mikus G
Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
